Robert Goldstein, MD
Gastroenterology · Levittown, PANPI 1992730279
Payments from drug & device makers
Across 494 payments — averaging $19.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Redhill Biopharma Inc.$2K
- Johnson & Johnson$809
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$803
- Braintree Laboratories, Inc.$626
- Ironwood Pharmaceuticals, Inc$428
- plus $3K from 29 others
What the payments were for
- Consulting fees$1,66517%
- Food & beverage$8,11382%
- Education$220%
- Gifts$761%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 189 | $2,267 |
| Redhill Biopharma Inc. | 15 | $1,870 |
| Johnson & Johnson | 34 | $809 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 56 | $803 |
| Braintree Laboratories, Inc. | 24 | $626 |
| Ironwood Pharmaceuticals, Inc | 24 | $428 |
| Sanofi | 19 | $410 |
| Madrigal Pharmaceuticals | 16 | $409 |
| Gilead | 17 | $301 |
| Pfizer | 13 | $246 |
| Ardelyx, Inc. | 10 | $235 |
| Bristol Myers Squibb | 11 | $211 |
| Medtronic(2 entities) | 3 | $174 |
| Lilly USA, LLC | 7 | $166 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $165 |
| Ferring Pharmaceuticals Inc. | 9 | $144 |
| QOL Medical, LLC | 7 | $99 |
| Regeneron Healthcare Solutions, Inc. | 4 | $87 |
| Evoke Pharma, Inc. | 3 | $57 |
| Intercept Pharmaceuticals, Inc. | 3 | $56 |
| Merck | 3 | $43 |
| Phathom Pharmaceuticals, Inc. | 2 | $35 |
| Digestive Care, Inc. | 1 | $34 |
| Abbott | 1 | $29 |
| Sun Pharmaceutical Industries Inc. | 1 | $25 |
| Vivus LLC | 2 | $24 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Echosens North America, Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $16 |
| Shionogi Inc | 1 | $15 |
| Fresenius Kabi USA, LLC | 1 | $15 |
| AstraZeneca | 1 | $12 |
| Concordia Pharmaceuticals Inc. | 1 | $11 |
| Romark Laboratories, LC | 1 | $11 |
| Intra-sana Laboratories | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,876 in reported general payments places this provider in the 75th percentile of 935 gastroenterology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 41 | $91,089 |
| LinzessLinaclotide | 87 | $71,417 |
| XifaxanRifaximin | 15 | $45,254 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 146 | $23,255 |
| PentasaMesalamine | 16 | $15,632 |
| Mesalamine | 29 | $11,725 |
| VoqueznaVonoprazan Fumarate | 13 | $10,869 |
| Omeprazole | 729 | $8,600 |
| Sucralfate | 42 | $7,335 |
| Dexlansoprazole DrDexlansoprazole | 17 | $6,630 |
| Famotidine | 313 | $5,611 |
| Pantoprazole Sodium | 394 | $5,593 |
| Tenofovir Disoproxil Fumarate | 12 | $4,582 |
| Dicyclomine Hcl | 135 | $3,474 |
| Budesonide EcBudesonide | 26 | $2,313 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $2,267 | $162,507128 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $803 | $45,25415 claims |
| Braintree Laboratories, Inc.Sutab | $626 | $23,255146 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $35 | $10,86913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 935 gastroenterology providers in Pennsylvania.
Other gastroenterology in Levittown
- Kuchikala ReddyPhiladelphia$6.5M
- Glenn FreedPottsville$3.8M
- Nirav ShahWyomissing$3.5M
- Jaideep BehariPittsburgh$2.7M
- Adnan AhmadCamp Hill$2.1M
- Frederick RuthardtUniontown$1.7M
- Adam PeytonAllentown$1.6M
- Dina Halegoua de MarzioPhiladelphia$1.5M
- Miguel RegueiroPittsburgh$1.5M
- Gary FalkPhiladelphia$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.